enow.com Web Search

  1. Ads

    related to: ovarian cancer approved drugs for women

Search results

  1. Results from the WOW.Com Content Network
  2. US FDA grants full approval to AbbVie's ovarian cancer therapy

    www.aol.com/news/us-fda-grants-full-approval...

    (Reuters) -The U.S. Food and Drug Administration said on Friday it had granted traditional approval for AbbVie's "guided missile" cancer therapy, Elahere, for patients with a type of ovarian ...

  3. Pafolacianine - Wikipedia

    en.wikipedia.org/wiki/Pafolacianine

    Scientists from Purdue University designed and developed OTL38 and licensed it to On Target Laboratories in 2013. [9] [10] The safety and effectiveness of pafolacianine was evaluated in a randomized, multi-center, open-label study of women diagnosed with ovarian cancer or with high clinical suspicion of ovarian cancer who were scheduled to undergo surgery.

  4. AstraZeneca-Merck Ovarian Cancer Treatment Gets FDA Approval

    www.aol.com/news/astrazeneca-merck-ovarian...

    The U.S. Food and Drug Administration (FDA) approved a treatment developed by AstraZeneca (AZN) and Merck Co. (MRK) for advanced ovarian cancer.The FDA approved the ovarian drug Lynparza to be ...

  5. Mirvetuximab soravtansine - Wikipedia

    en.wikipedia.org/wiki/Mirvetuximab_soravtansine

    Mirvetuximab soravtansine, sold under the brand name Elahere, is a medication used as a treatment for epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. [ 2 ] [ 5 ] Mirvetuximab soravtansine is a folate receptor alpha directed antibody and microtubule inhibitor conjugate.

  6. PARP inhibitor - Wikipedia

    en.wikipedia.org/wiki/PARP_inhibitor

    Rucaparib: On December 19, 2016, the US FDA granted accelerated approval for previously treated BRCA-mutant ovarian cancer. [8] In April 2018 it was granted FDA approval. Niraparib: In March 2017 approved by US FDA for epithelial ovarian, fallopian tube, and primary peritoneal cancer. [9] [10] Inhibitor of PARP1 and PARP2. [11]

  7. Women with difficult-to-treat ovarian cancer offered hope by ...

    www.aol.com/women-difficult-treat-ovarian-cancer...

    Professor Susana Banerjee, from the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research said the findings were ‘significant’. Women with difficult-to-treat ovarian cancer ...

  8. Trabectedin - Wikipedia

    en.wikipedia.org/wiki/Trabectedin

    Trabectedin, sold under the brand name Yondelis, is an antitumor chemotherapy medication for the treatment of advanced soft-tissue sarcoma and ovarian cancer. [3] [4]The most common adverse reactions include nausea, fatigue, vomiting, constipation, decreased appetite, diarrhea, peripheral edema, dyspnea, and headache.

  9. Antihormone therapy - Wikipedia

    en.wikipedia.org/wiki/Antihormone_therapy

    Ovarian suppression is known to slow the growth of hormone receptor-positive breast cancer in premenopausal women [13] and can also help preserve fertility during chemotherapy. [14] Ovarian suppression through drugs temporarily shuts down the ovaries preventing the production of oestrogen , thus slowing the rate of growth of hormone receptor ...

  1. Ads

    related to: ovarian cancer approved drugs for women